Bullous pemphigoid (BP) is the most common autoimmune blistering disorder affecting older adults, with the worldwide incidence ranging from 12.1 to 43.0 per 1 million persons per year.
1-7 Bullous pemphigoid is characterized by the presence of autoantibodies targeting BP antigens 180 and 230, leading to the degradation of the basement membrane zone.
7 Bullous pemphigoid has a chronic relapsing course that requires long-term systemic corticosteroids or other immunosuppressants. Complications such as infections or adverse effects of medical therapies lead to 3.6-fold higher mortality rates in patients with BP compared with the age-matched general population.
8